Mike HoneyHere's the latest variant picture for the United Kingdom.
"FLuQE" KP.3 appears to be taking over rapidly from "FLiRT" lineage KP.2, with a growth advantage of 3% per day (20% per week).
Here's the latest variant picture for Canada.
"FLuQE" sibling KP.3 has continued to dominate "FLIRT" KP.2.
Here's the latest variant picture for the United States.
Still hard to pick a winner between "FLiRT" lineages KP.2 and JN.1.16.1, and "FLuQE" KP.3.
Recent sample sizes are very small, so the last few days shown might not be representative.
Here's the latest variant picture for Australia.
"FLuQE" sibling KP.3 continues to dominate "FLiRT" KP.2 and show strong growth in most states. Data from Victoria lags by almost a month now - the dismal routine.
Here's the latest variant picture with a global scope.
The battle for dominance between "FLIRT" KP.2 and "FLuQE" sibling KP.3 continues, with no clear winnder.
Sample sizes are very small after late May, so might not be representative.
Here's the latest variant picture for the United Kingdom.
"FLiRT" lineage KP.2 remains dominant, but "FLuQE" sibling KP.3 is now challenging.
Here's the latest variant picture for Canada.
"FLuQE" sibling KP.3 has continued to dominate "FLIRT" KP.2 during May.
Here's the latest variant picture for the United States.
"FLiRT" lineage KP.2 has been dominant, but might be under challenge by "FLiRT" JN.1.16.1 and "FLuQE" KP.3. This suggests potential for rapid acceleration from a triple-wave of new variants, each with unique immune evasion.
Here's the latest variant picture with a global scope.
"FLuQE" sibling KP.3 seems clearly dominant over "FLIRT" KP.2 now.
Sample sizes are very small after mid-May, so might not be representative.
Here's the latest variant picture for the United Kingdom.
"FLiRT" lineage KP.2 remains dominant. "FLuQE" sibling KP.3 is also growing.
